“Late” Withdrawal Syndrome after Carbamazepine In Utero Exposure in a CYP2C9 Slow Metabolizer Newborn

We report a case of carbamazepine withdrawal syndrome following in utero exposure to carbamazepine related to a pharmacogenetic predisposition factor. The infant was born at 37 1/7 weeks’ gestation by cesarean section to a mother treated for epilepsy with carbamazepine. One hour and thirty minutes a...

Descripción completa

Detalles Bibliográficos
Autores principales: Passia, Evangelia, Rock, Nathalie, Pfister, Riccardo E., Ing Lorenzini, Kuntheavy R., Desmeules, Jules, Samer, Caroline F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399605/
https://www.ncbi.nlm.nih.gov/pubmed/28484392
http://dx.doi.org/10.3389/fphar.2017.00217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399605/
https://www.ncbi.nlm.nih.gov/pubmed/28484392
http://dx.doi.org/10.3389/fphar.2017.00217

Ejemplares similares